Artiva Biotherapeutics awarded CEO Aslan Fred 110,000 shares at $0 on 2026-09-15, while also granting 315,000 derivative securities. The resulting holdings give investors a clear view of Fred’s post-award position: 1,604,765 shares and 315,000 derivative securities.

Key Highlights

  • Aslan Fred’s resulting Artiva Biotherapeutics share holding was 1,604,765.
  • The executive received 315,000 derivative securities on 15 September 2026.
  • The share award represented about 6.9% of Fred’s resulting share holding.

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) awarded Chief Executive Officer Aslan Fred 110,000 shares at $0 on 15 September 2026. The transaction was recorded under code A. The award was recorded for Artiva Biotherapeutics shares.

Share Award and Resulting Position

Fred’s share holding following the transaction stood at 1,604,765. The 110,000-share award represented about 6.9% of that resulting holding. The transaction date was 15 September 2026. Artiva Biotherapeutics identified Fred as its Chief Executive Officer in the transaction record.

Derivative Securities Awarded

The same transaction record showed an award of 315,000 derivative securities to Fred. His resulting derivative-securities holding was 315,000. The derivative-securities award represented about 100.0% of his resulting derivative-securities holding. Code A applied to that award as well.